Article
Role of interleukin-21 and interleukin-21 receptor polymorphisms in the treatment of HBeAg-positive chronic hepatitis B patients with peginterferon.
Medicine - 1 Jun 2018
Wang Xia, Xu Zhi-Qiang, Fu Juan-Juan, Cheng Li-Wei, Li Yan, Li Li, Pan Xiu-Cheng
Abstract excerpt
The aim of this study was to evaluate the relationship between interleukin-21 (IL-21) and interleukin-21 receptor (IL-21R) polymorphisms and the response to peginterferon alfa (PEG-IFN α) therapy in HBeAg-positive chronic hepatitis B (CHB) patients.A total of 143 HBeAg-positive CHB patients treated for 48 weeks with PEG-IFN α and followed up for 24 weeks post-treatment were retrospectively evaluated. Genotypes...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
